Annual EBITDA
-$118.42 M
+$20.88 M+14.99%
31 December 2023
Summary:
Karyopharm Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$118.42 million, with the most recent change of +$20.88 million (+14.99%) on 31 December 2023. During the last 3 years, it has fallen by -$21.44 million (-22.10%). KPTI annual EBITDA is now -1057.83% below its all-time high of -$10.23 million, reached on 31 December 2011.KPTI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$20.58 M
-$53.48 M-162.54%
30 September 2024
Summary:
Karyopharm Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$20.58 million, with the most recent change of -$53.48 million (-162.54%) on 30 September 2024. Over the past year, it has increased by +$14.85 million (+41.91%). KPTI quarterly EBITDA is now -144.08% below its all-time high of $46.68 million, reached on 31 December 2021.KPTI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$54.42 M
+$7.76 M+12.49%
30 September 2024
Summary:
Karyopharm Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$54.42 million, with the most recent change of +$7.76 million (+12.49%) on 30 September 2024. Over the past year, it has increased by +$64.00 million (+54.05%). KPTI TTM EBITDA is now -1411.27% below its all-time high of -$3.60 million, reached on 30 September 2012.KPTI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KPTI EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +41.9% | +54.0% |
| 3 y3 years | -22.1% | -144.1% | +43.9% |
| 5 y5 years | +35.3% | +50.9% | +70.3% |
KPTI EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -22.1% | +15.0% | -144.1% | +51.6% | at high | +60.9% |
| 5 y | 5 years | -22.1% | +35.3% | -144.1% | +60.4% | at high | +70.3% |
| alltime | all time | -1057.8% | +35.3% | -144.1% | +67.3% | -1411.3% | +73.6% |
Karyopharm Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.58 M(-162.5%) | -$54.42 M(-12.5%) |
| June 2024 | - | $32.90 M(-205.0%) | -$62.19 M(-48.9%) |
| Mar 2024 | - | -$31.32 M(-11.6%) | -$121.72 M(+2.8%) |
| Dec 2023 | -$118.42 M(-15.0%) | -$35.42 M(+25.0%) | -$118.42 M(+2.6%) |
| Sept 2023 | - | -$28.34 M(+6.4%) | -$115.44 M(-1.4%) |
| June 2023 | - | -$26.64 M(-5.0%) | -$117.08 M(-11.9%) |
| Mar 2023 | - | -$28.02 M(-13.6%) | -$132.92 M(-4.6%) |
| Dec 2022 | -$139.31 M(+43.6%) | -$32.44 M(+8.2%) | -$139.31 M(+131.4%) |
| Sept 2022 | - | -$29.98 M(-29.4%) | -$60.19 M(-18.3%) |
| June 2022 | - | -$42.48 M(+23.5%) | -$73.72 M(-7.2%) |
| Mar 2022 | - | -$34.41 M(-173.7%) | -$79.46 M(-18.1%) |
| Dec 2021 | -$96.98 M(-42.2%) | $46.68 M(-207.3%) | -$96.98 M(-46.0%) |
| Sept 2021 | - | -$43.51 M(-9.8%) | -$179.69 M(-1.6%) |
| June 2021 | - | -$48.22 M(-7.2%) | -$182.60 M(+5.1%) |
| Mar 2021 | - | -$51.94 M(+44.1%) | -$173.67 M(+3.5%) |
| Dec 2020 | -$167.85 M(-8.2%) | -$36.03 M(-22.4%) | -$167.85 M(-3.4%) |
| Sept 2020 | - | -$46.41 M(+18.1%) | -$173.76 M(+5.1%) |
| June 2020 | - | -$39.29 M(-14.8%) | -$165.35 M(-0.5%) |
| Mar 2020 | - | -$46.11 M(+10.0%) | -$166.13 M(-9.2%) |
| Dec 2019 | -$182.93 M(+4.4%) | -$41.93 M(+10.3%) | -$182.93 M(-6.9%) |
| Sept 2019 | - | -$38.01 M(-5.2%) | -$196.50 M(-4.8%) |
| June 2019 | - | -$40.08 M(-36.3%) | -$206.37 M(+3.3%) |
| Mar 2019 | - | -$62.91 M(+13.3%) | -$199.78 M(+14.1%) |
| Dec 2018 | -$175.15 M | -$55.51 M(+15.9%) | -$175.15 M(+11.3%) |
| Sept 2018 | - | -$47.88 M(+43.0%) | -$157.31 M(+12.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | -$33.49 M(-12.5%) | -$140.31 M(+2.9%) |
| Mar 2018 | - | -$38.28 M(+1.6%) | -$136.39 M(+6.4%) |
| Dec 2017 | -$128.21 M(+17.9%) | -$37.66 M(+22.0%) | -$128.21 M(+10.3%) |
| Sept 2017 | - | -$30.88 M(+4.4%) | -$116.24 M(+4.8%) |
| June 2017 | - | -$29.57 M(-1.7%) | -$110.92 M(-0.6%) |
| Mar 2017 | - | -$30.10 M(+17.1%) | -$111.65 M(+2.7%) |
| Dec 2016 | -$108.72 M(-8.2%) | -$25.69 M(+0.5%) | -$108.72 M(-3.1%) |
| Sept 2016 | - | -$25.56 M(-15.6%) | -$112.16 M(-4.2%) |
| June 2016 | - | -$30.30 M(+11.5%) | -$117.04 M(-2.1%) |
| Mar 2016 | - | -$27.17 M(-6.7%) | -$119.60 M(+1.0%) |
| Dec 2015 | -$118.44 M(+57.0%) | -$29.13 M(-4.3%) | -$118.44 M(+2.9%) |
| Sept 2015 | - | -$30.45 M(-7.3%) | -$115.06 M(+10.4%) |
| June 2015 | - | -$32.86 M(+26.3%) | -$104.25 M(+18.7%) |
| Mar 2015 | - | -$26.01 M(+1.1%) | -$87.80 M(+16.4%) |
| Dec 2014 | -$75.45 M(+123.2%) | -$25.74 M(+31.1%) | -$75.45 M(+22.1%) |
| Sept 2014 | - | -$19.64 M(+19.7%) | -$61.82 M(+20.1%) |
| June 2014 | - | -$16.41 M(+20.0%) | -$51.47 M(+22.8%) |
| Mar 2014 | - | -$13.67 M(+12.9%) | -$41.90 M(+23.9%) |
| Dec 2013 | -$33.80 M(+114.4%) | -$12.11 M(+30.4%) | -$33.80 M(+30.5%) |
| Sept 2013 | - | -$9.28 M(+35.8%) | -$25.90 M(+28.1%) |
| June 2013 | - | -$6.83 M(+22.6%) | -$20.22 M(+51.1%) |
| Mar 2013 | - | -$5.58 M(+32.5%) | -$13.39 M(+71.4%) |
| Dec 2012 | -$15.77 M(+54.1%) | -$4.21 M(+16.9%) | -$7.81 M(+116.9%) |
| Sept 2012 | - | -$3.60 M | -$3.60 M |
| Dec 2011 | -$10.23 M | - | - |
FAQ
- What is Karyopharm Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly EBITDA year-on-year change?
- What is Karyopharm Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics TTM EBITDA year-on-year change?
What is Karyopharm Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of KPTI is -$118.42 M
What is the all time high annual EBITDA for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$10.23 M
What is Karyopharm Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of KPTI is -$20.58 M
What is the all time high quarterly EBITDA for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $46.68 M
What is Karyopharm Therapeutics quarterly EBITDA year-on-year change?
Over the past year, KPTI quarterly earnings before interest, taxes, depreciation & amortization has changed by +$14.85 M (+41.91%)
What is Karyopharm Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of KPTI is -$54.42 M
What is the all time high TTM EBITDA for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$3.60 M
What is Karyopharm Therapeutics TTM EBITDA year-on-year change?
Over the past year, KPTI TTM earnings before interest, taxes, depreciation & amortization has changed by +$64.00 M (+54.05%)